Neuropeptide SF (mouse, rat)
Cat. No. 3647
Biological ActivityNeuropeptide FF receptor agonist (Ki values are 48.4 and 12.1 nM for NPFF1 and NPFF2, respectively). Potentiates the antinociceptive action of morphine in vivo and reverses the loss of morphine potency in tolerant animals. Also increases the amplitude of the sustained current of heterologously expressed acid sensing ion channel 3 (ASIC3) (EC50 ~ 50 μM).
(Modifications: Phe-8 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Jhamandas et al (2006) Facilitation of spinal morphine analgesia in normal and morphine tolerant animals by neuropeptide SF and related peptides. Peptides 27 953. PMID: 16515821.
Deval et al (2003) Effects of neuropeptide SF and related peptides on acid sensing ion channel 3 and sensory neuron excitability. Neuropharmacology 44 662. PMID: 12668052.
Gouarderes et al (2002) Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [125I]EYF as selective radioligands. Neurosci. 115 349.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Neuropeptide SF (mouse, rat) from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Neuropeptide SF (mouse, rat), supplier, NPFF1, NPFF2, agonists, Neuropeptides, FF, AF, Receptors, FF/AF, acid, sensing, ion, channel, 3, ASIC3, NeuropeptideSF, (mouse, rat), npffr1, npffr2, ASIC, Tocris Bioscience, Neuropeptide FF/AF Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands